Lahey Hospital & Medical Center

Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy

Retrieved on:

Tuesday, November 7, 2023

CPET, Lahey Hospital & Medical Center, KCCQ, Medical Center, Disease, Clinical trial, Heart failure with preserved ejection fraction, Safety, Patient, Heart failure, Ex-gay movement, Medical imaging, Pharmaceutical industry

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to improve patient symptoms and function by enhancing cellular energetics, today announced positive topline results from the Phase 2 IMPROVE-HCM clinical trial, evaluating ninerafaxstat, a novel cardiac mitotrope and partial fatty acid oxidation (pFOX) inhibitor, in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM), a large orphan disease with no approved therapies.

Key Points:

Treatment with ninerafaxstat was well tolerated and no safety signals were observed.
At 12-weeks, treatment with ninerafaxstat showed a statistically significant improvement in a robust functional cardiopulmonary exercise test (CPET) measure of established prognostic significance in patients with nHCM and heart failure with preserved ejection fraction (HFpEF).
“Based on the topline results from IMPROVE-HCM, we are focused on advancing ninerafaxstat into a Phase 3 clinical trial of patients with nHCM and plan to meet with regulatory agencies within the coming months to confirm trial design.
Imbria anticipates sharing full data from the IMPROVE-HCM Phase 2 clinical trial at an upcoming medical conference.

Cytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions

Retrieved on:

Friday, October 6, 2023

SEQUOIA-HCM enrolled a total of 282 patients, with one third from the United States, one half from Europe and Israel, and the remainder from China.

Key Points:

SEQUOIA-HCM enrolled a total of 282 patients, with one third from the United States, one half from Europe and Israel, and the remainder from China.
Background medical therapy consisted of beta-blockers (61%), calcium channel blockers (26.6%), and disopyramide (12.8%); combination background therapy was permitted.
At baseline, 75.9% of patients were NYHA functional class II, 23.8% were functional class III, and 0.4% were functional class IV.
Key baseline characteristics that remain blinded include left ventricular ejection fraction (LVEF), resting and Valsalva LVOT-G, and NT-proBNP.

ABMS Announces Class of 2023-2024 Visiting Scholars

Retrieved on:

Monday, September 11, 2023

Radiology, American Board of Medical Specialties, Medicine, ABMS, Research, Mentorship, Assistant, MS, Certification, Medical specialty, American Board of Commissioners for Foreign Missions, Johns Hopkins University, Elective surgery, MPH, Lahey Hospital & Medical Center, Nursing, MD

CHICAGO, Sept. 11, 2023 /PRNewswire/ -- The American Board of Medical Specialties (ABMS) has selected thirteen outstanding individuals to participate in its 2023-2024 Visiting Scholars Program™. Established in 2014, the one-year, part-time program supports early-career physicians and researchers in scholarship and leadership development focusing on initial and continuing board certification. Each Visiting Scholar receives a $15,000 financial award.

Key Points:

Thirteen scholars will receive financial awards for research in physician well-being, quality improvement, and diversity, equity, and innovations in assessment
CHICAGO, Sept. 11, 2023 /PRNewswire/ -- The American Board of Medical Specialties (ABMS) has selected thirteen outstanding individuals to participate in its 2023-2024 Visiting Scholars Program™.
Established in 2014, the one-year, part-time program supports early-career physicians and researchers in scholarship and leadership development focusing on initial and continuing board certification.
"We are pleased to support a record number of ABMS Visiting Scholars this year," stated Greg Ogrinc, MD, MS, ABMS Senior Vice President, Certification Standards and Programs.
ABMS Visiting Scholars are selected based on the quality of their proposed research project, the relevance of their research to the ABMS mission and the certification community, and demonstration of making significant progress on the project during the scholar year.

binx health Announces Time and Motion Study Data Shared at STI & HIV 2023 World Congress in Chicago, IL

Retrieved on:

Monday, August 14, 2023

The Study was a head-to-head comparison of the workflow for the binx io chlamydia (CT) and gonorrhea (NG) test compared to their standard of care laboratory-based test.

Key Points:

The Study was a head-to-head comparison of the workflow for the binx io chlamydia (CT) and gonorrhea (NG) test compared to their standard of care laboratory-based test.
"The data further support that the binx io provided test results reasonable for a single patient-visit compared to 16 hours for the laboratory-based results.
This time-to-result is extremely important for providing clinically actionable information and improving the quality of a patient’s care."
Together, Cincinnati Children’s, Johns Hopkins, and binx health play critical roles in STI diagnosis and treatment by reducing barriers to adoption and shedding light on the positive impact of point-of-care testing in clinical settings.

NRC Health unveils winners of 2023 patient experience and loyalty awards

Retrieved on:

Tuesday, August 8, 2023

LINCOLN, Neb., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NRC Health , a leading provider of Human Understanding® and data-driven insights, is pleased to announce the recipients of the 2023 Consumer Loyalty Awards and the Excellence in Patient Experience Awards.

Key Points:

LINCOLN, Neb., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NRC Health , a leading provider of Human Understanding® and data-driven insights, is pleased to announce the recipients of the 2023 Consumer Loyalty Awards and the Excellence in Patient Experience Awards.
NRC Health's Consumer Loyalty Award winners lead the way in delivering exceptional patient experiences.
Elevating the patient experience remains a priority in healthcare, and NRC Health's 2023 Excellence in Patient Experience Award winners have demonstrated outstanding commitment to individualized and human-centered care.
To check whether your local hospital is a 2023 honoree, see the full lists of winning organizations for both the 2023 Consumer Loyalty Awards and the 2023 Excellence in Patient Experience Awards .

NRC Health unveils winners of 2023 patient experience and loyalty awards

Retrieved on:

Tuesday, August 8, 2023

LINCOLN, Neb., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NRC Health , a leading provider of Human Understanding® and data-driven insights, is pleased to announce the recipients of the 2023 Consumer Loyalty Awards and the Excellence in Patient Experience Awards.

Key Points:

LINCOLN, Neb., Aug. 08, 2023 (GLOBE NEWSWIRE) -- NRC Health , a leading provider of Human Understanding® and data-driven insights, is pleased to announce the recipients of the 2023 Consumer Loyalty Awards and the Excellence in Patient Experience Awards.
NRC Health's Consumer Loyalty Award winners lead the way in delivering exceptional patient experiences.
Elevating the patient experience remains a priority in healthcare, and NRC Health's 2023 Excellence in Patient Experience Award winners have demonstrated outstanding commitment to individualized and human-centered care.
To check whether your local hospital is a 2023 honoree, see the full lists of winning organizations for both the 2023 Consumer Loyalty Awards and the 2023 Excellence in Patient Experience Awards .

The Inner Circle Acknowledges, Mike Cotzas as a Pinnacle Life Healthcare Professional for his contributions to the field of Orthodontics

Retrieved on:

Friday, August 4, 2023

NEW CANAAN, Conn., Aug. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Mike Cotzas is acknowledged as a Pinnacle Life Healthcare Professional for his contributions to the field of Orthodontics.

Key Points:

NEW CANAAN, Conn., Aug. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Mike Cotzas is acknowledged as a Pinnacle Life Healthcare Professional for his contributions to the field of Orthodontics.
Dr. Cotzas pursued higher education at New York University where he earned a Bachelor's degree in Biology.
A devoted professional in his field, Dr. Cotzas attends conferences and completes continuing education courses to keep abreast of the latest innovations in orthodontics.
Orthodontists, like Dr. Cotzas, are responsible for identifying problems with teeth, jaws, and fixing the bite for proper chewing.

The Inner Circle Acknowledges, Helen Khilkin-Sogoloff as a Pinnacle Life Professional for her contributions to the field of Osteopathic Medicine

Retrieved on:

Tuesday, June 20, 2023

NEW YORK, June 20, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Helen Khilkin-Sogoloff is recognized as a Pinnacle Life Professional for her contributions to the field of Osteopathic Medicine.

Key Points:

NEW YORK, June 20, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Helen Khilkin-Sogoloff is recognized as a Pinnacle Life Professional for her contributions to the field of Osteopathic Medicine.
Dr. Khilkin-Sogoloff pursued a Doctor of Osteopathic Medicine degree from the New York College of Osteopathic Medicine in 1994.
The doctor explained that pulmonology is a medical specialty that deals with asthma; COPD; lung cancer diagnosis; interstitial lung disease; infections of the lungs; and post-COVID pulmonary complications.
Aside from her professional pursuits, the doctor enjoys skiing, hiking, gardening, and spending time with her family.

Lahey Hospital & Medical Center Agrees to become One of the U.S. Sites for the LIBERTY® Robotic System’s First Human Trial

Retrieved on:

Thursday, May 25, 2023

The Hague, Institutional review board, Investigational New Drug, ZEUS robotic surgical system, Clinical trial, IRB, Medical Center, Trial, Investigational device exemption, Lahey Hospital & Medical Center, Faculty, IDE, FDA, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Medical device, Pharmaceutical industry

HINGHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced that it has successfully achieved another major milestone representing the next step toward the regulatory and commercial paths for the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system. Lahey Hospital & Medical Center, a world-renowned tertiary academic medical center based in Burlington, Mass., is now expected to be one of the U.S. sites for the first-ever human trial of the LIBERTY Robotic Surgical System. Microbot Medical will work closely with the research team and physician faculty at Lahey to support innovative ways to improve patient care using the LIBERTY Robotic Surgical System.

Key Points:

Lahey Hospital & Medical Center, a world-renowned tertiary academic medical center based in Burlington, Mass., is now expected to be one of the U.S. sites for the first-ever human trial of the LIBERTY Robotic Surgical System.
Microbot Medical will work closely with the research team and physician faculty at Lahey to support innovative ways to improve patient care using the LIBERTY Robotic Surgical System.
“This is another meaningful milestone for Microbot Medical, and clearly demonstrates that we are taking the necessary steps toward future commercialization of the LIBERTY Robotic Surgical System,” commented Harel Gadot, Chairman, President & CEO of Microbot Medical.
“We believe our continued momentum and the performance of the system, along with the rigorous process we are adhering to, has made today’s development possible.

The I-PASS Patient Safety Institute Hires Risk and Insurance Veteran Bob Hanscom as a Strategic Advisor

Retrieved on:

Tuesday, May 23, 2023

I-PASS , the gold standard for reducing preventable medical errors and patient harm through improved clinical handoffs, announced today the appointment of Bob Hanscom as a Strategic Advisor.

Key Points:

I-PASS , the gold standard for reducing preventable medical errors and patient harm through improved clinical handoffs, announced today the appointment of Bob Hanscom as a Strategic Advisor.
Hanscom will collaborate closely with the I-PASS leadership team to develop and deliver strategies to help healthcare providers drive a culture of safety through communication.
Research demonstrates that I-PASS’s structured patient handoffs can dramatically reduce these adverse events by nearly 50%.
“Bob has achieved great success during his career in risk management across healthcare organizations, and we’re excited to bring his wealth of knowledge and experience to aid in our clients’ journey to a culture of safety,” said William Floyd, CEO of the I-PASS Patient Safety Institute.